Phospho-tau with subthreshold tau-PET predicts increased tau accumulation rates in amyloid-positive individuals
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Different tau biomarkers become abnormal at different stages of Alzheimer’s disease, with CSF phospho-tau typically becoming elevated at subthreshold levels of tau-PET binding. To capitalize on the temporal order of tau biomarker-abnormality and capture the earliest changes of tau accumulation, we implemented an observational study design to examine longitudinal changes in tau-PET, cortical thickness and cognitive decline in amyloid-β-positive individuals with elevated CSF p-tau levels (P+) but subthreshold Tau-PET retention (T−). To this end, individuals without dementia (i.e. cognitively unimpaired or mild cognitive impairment, n = 231) were selected from the BioFINDER-2 study. Amyloid-β-positive (A+) individuals were categorized into biomarker groups based on cut-offs for abnormal CSF p-tau217 and 18F-RO948 (Tau) PET, yielding groups of tau-concordant-negative (A+P−T−; n = 30), tau-discordant (i.e. A+P+T−; n = 48) and tau-concordant-positive (A+P+T+; n = 18) individuals. In addition, 135 amyloid-β-negative, tau-negative, cognitively unimpaired individuals served as controls. Differences in annual change in regional tau-PET, cortical thickness and cognition between the groups were assessed using general linear models, adjusted for age, sex, clinical diagnosis and (for cognitive measures only) education. Mean follow-up time was ∼2 years. Longitudinal increase in tau-PET was faster in the A+P+T− group than in the control and A+P−T− groups across medial temporal and neocortical regions, with the highest accumulation rates in the medial temporal lobe. The A+P+T− group showed a slower rate of increase in tau-PET compared to the A+P+T+ group, primarily in neocortical regions. We did not detect differences in yearly change in cortical thickness or in cognitive decline between the A+P+T− and A+P−T− groups. The A+P+T+ group, however, showed faster cognitive decline compared to all other groups. Altogether, these findings suggest that the A+P+T− biomarker profile in persons without dementia is associated with an isolated effect on increased tau-PET accumulation rates but not on cortical thinning and cognitive decline. While this suggests that the tau-discordant biomarker profile is not strongly associated with short-term clinical decline, this group does represent an interesting population for monitoring the effects of interventions with disease-modifying agents on tau accumulation in early Alzheimer’s disease, and for examining the emergence of tau aggregates in Alzheimer’s disease. Further, we suggest updating the AT(N) criteria for Alzheimer’s disease biomarker classification to APT(N).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Scheltens, P., De Strooper, B., Kivipelto, M., Holstege, H., Chételat, G., Teunissen, C. E., Cummings, J., & van der Flier, W. M. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32205-4 · Cited by 5,465
Stages of the Pathologic Process in Alzheimer Disease: Age Categories From 1 to 100 Years
Braak, H., Thal, D. R., Ghebremedhin, E., & Del Tredici, K. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e318232a379 · Cited by 2,194 · cited 1×
“Given our hypothesis that isolated CSF p-tau positivity might predict the earliest stages of tau accumulation on tau-PET, 31,32 we also assessed tau-PET within individual regions that were recently identified to show a temporal order of abnormality in a tau-PET staging scheme.”
Nelson, P. T., Alafuzoff, I., Bigio, E. H., Bouras, C., Braak, H., Cairns, N. J., Castellani, R. J., Crain, B. J., Davies, P., Tredici, K. D., et al. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31825018f7 · Cited by 2,050
Cerebrospinal fluid and plasma biomarkers in Alzheimer disease
Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863 · cited 1×
“…regions are: entorhinal cortex, Brodmann area 35 (overlapping with the trans entorhinal cortex), anterior hippocampus, posterior hippocampus, Brodmann area 36, parahippocampal cortex, middle temporal cortex, inferior temporal cortex, inferior parietal cortex, isthmus cingulate cortex and precuneus.”
Donanemab in Early Alzheimer’s Disease
Mintun, M. A., Lo, A. C., Duggan Evans, C., Wessels, A. M., Ardayfio, P. A., Andersen, S. W., Shcherbinin, S., Sparks, J., Sims, J. R., Brys, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2100708 · Cited by 1,728 · cited 2×
“We also did not account for the possible confounding effects of co-pathologies such as vascular injury and TDP-43 deposition on longitudinal tau, atrophy and cognition between groups.”
Palmqvist, S., Janelidze, S., Quiroz, Y. T., Zetterberg, H., Lopera, F., Stomrud, E., Su, Y., Chen, Y., Serrano, G. E., Leuzy, A., et al. (2020) · JAMA · doi:10.1001/jama.2020.12134 · Cited by 1,603 · cited 3×
“21,22,26 Each tau-PET SUVR image was rigidly co-reregistered to a high-resolution T 1 - weighted MRI (Siemens3 T MAGNETOM Prisma) scan, performed a maximum of 6 months from the tau-PET scan.”
Self-citationCSF markers for incipient Alzheimer's disease
Blennow, K., & Hampel, H. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00530-1 · Cited by 1,291 · cited 1×
“10,47,48 By implementing a multi-modal approach and leveraging the knowledge about what CSF and PET biomarkers for tau represent, one can better elucidate the mechanisms underlying the emergence and spread of tau pathology in Alzheimer’s disease.”
PET Imaging of Tau Deposition in the Aging Human Brain
Schöll, M., Lockhart, S. N., Schonhaut, D. R., O’Neil, J. P., Janabi, M., Ossenkoppele, R., Baker, S. L., Vogel, J. W., Faria, J., Schwimmer, H. D., et al. (2016) · Neuron · doi:10.1016/j.neuron.2016.01.028 · Cited by 1,214 · cited 1×
“49 Furthermore, entorhinal tau is often seen in normal ageing, 50 and is not necessarily specific to individuals on the Alzheimer’s disease continuum.”
Self-citationTau PET patterns mirror clinical and neuroanatomical variability in Alzheimer’s disease
Ossenkoppele, R., Schonhaut, D. R., Schöll, M., Lockhart, S. N., Ayakta, N., Baker, S. L., O’Neil, J. P., Janabi, M., Lazaris, A., Cantwell, A., et al. (2016) · Brain · doi:10.1093/brain/aww027 · Cited by 1,185
Self-citationBiomarkers for neurodegenerative diseases
Hansson, O. (2021) · Nature Medicine · doi:10.1038/s41591-021-01382-x · Cited by 1,159
Self-citationDickerson, B. C., Bakkour, A., Salat, D. H., Feczko, E., Pacheco, J., Greve, D. N., Grodstein, F., Wright, C. I., Blacker, D., Rosas, H. D., et al. (2009) · Cerebral Cortex · doi:10.1093/cercor/bhn113 · Cited by 1,153
Defining imaging biomarker cut points for brain aging and Alzheimer's disease
Jack, C. R., Wiste, H. J., Weigand, S. D., Therneau, T. M., Lowe, V. J., Knopman, D. S., Gunter, J. L., Senjem, M. L., Jones, D. T., Kantarci, K., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.08.005 · Cited by 931
Jin, M., Shepardson, N., Yang, T., Chen, G., Walsh, D., & Selkoe, D. J. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1017033108 · Cited by 876 · cited 1×
“15,44 For tau-PET, neuropathology studies have revealed that it mainly reflects aggregated tau proteins into neuritic tau and neurofibrillary tangles, especially in the later stages of Alzheimer’s disease.”
The Preclinical Alzheimer Cognitive Composite: Measuring Amyloid-Related Decline
Donohue, M. C., Sperling, R. A., Salmon, D. P., Rentz, D. M., Raman, R., Thomas, R. G., Weiner, M., & Aisen, P. S. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.803 · Cited by 860
the Dominantly Inherited Alzheimer Network, Barthélemy, N. R., Li, Y., Joseph-Mathurin, N., Gordon, B. A., Hassenstab, J., Benzinger, T. L. S., Buckles, V., Fagan, A. M., Perrin, R. J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0781-z · Cited by 651
La Joie, R., Visani, A. V., Baker, S. L., Brown, J. A., Bourakova, V., Cha, J., Chaudhary, K., Edwards, L., Iaccarino, L., Janabi, M., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aau5732 · Cited by 612 · cited 2×
“In line with previous work indicating a close link between tau-PET and atrophy, 42 A+P+T+ cases (i.e. above threshold tau-PET) showed decreased cortical thickness already at the baseline visit.”
[ 18 F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease
Xia, C., Arteaga, J., Chen, G., Gangadharmath, U., Gomez, L. F., Kasi, D., Lam, C., Liang, Q., Liu, C., Mocharla, V. P., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.11.008 · Cited by 605
In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum
Cho, H., Choi, J. Y., Hwang, M. S., Kim, Y. J., Lee, H. M., Lee, H. S., Lee, J. H., Ryu, Y. H., Lee, M. S., & Lyoo, C. H. (2016) · Annals of Neurology · doi:10.1002/ana.24711 · Cited by 499
Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's disease
Janelidze, S., Stomrud, E., Smith, R., Palmqvist, S., Mattsson, N., Airey, D. C., Proctor, N. K., Chai, X., Shcherbinin, S., Sims, J. R., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15436-0 · Cited by 450 · cited 1×
“10 CSF p-tau measures soluble variants of tau 11 and has been shown to be sensitive to the earliest tau changes in Alzheimer’s disease.”
Self-citationFleisher, A. S., Pontecorvo, M. J., Devous, M. D., Lu, M., Arora, A. K., Truocchio, S. P., Aldea, P., Flitter, M., Locascio, T., Devine, M., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.0528 · Cited by 448 · cited 3×
“12 On the other hand, tau-PET ligands bind aggregated, insoluble paired helical filaments of tau 13,14 reflecting the pathological accumulation of tau aggregates, 15 and tau-PET shows particular sensitivity to tau pathology in later stages of Alzheimer’s disease.”
Palmqvist, S., Mattsson, N., Hansson, O., & Initiative, F. T. A. D. N. (2016) · Brain · doi:10.1093/brain/aww015 · Cited by 400
Self-citationPalmqvist, S., Zetterberg, H., Blennow, K., Vestberg, S., Andreasson, U., Brooks, D. J., Owenius, R., Hägerström, D., Wollmer, P., Minthon, L., et al. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.1358 · Cited by 368 · cited 1×
“21,24,25 Briefly, tau-PET scanning was performed using 18 F-RO948 on a digital Discovery MI scanner (GE Healthcare).”
Self-citationMattsson-Carlgren, N., Andersson, E., Janelidze, S., Ossenkoppele, R., Insel, P., Strandberg, O., Zetterberg, H., Rosen, H. J., Rabinovici, G., Chai, X., et al. (2020) · Science Advances · doi:10.1126/sciadv.aaz2387 · Cited by 359 · cited 4×
“15,44 For tau-PET, neuropathology studies have revealed that it mainly reflects aggregated tau proteins into neuritic tau and neurofibrillary tangles, especially in the later stages of Alzheimer’s disease.”
InfluentialSelf-citationOssenkoppele, R., Smith, R., Mattsson-Carlgren, N., Groot, C., Leuzy, A., Strandberg, O., Palmqvist, S., Olsson, T., Jögi, J., Stormrud, E., et al. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2021.1858 · Cited by 311 · cited 2×
“Furthermore, we used thresholds to determine CSF p-tau and tau-PET positivity based on Gaussian mixture models, while others have previously used alternative methods, 40,49 hampering a direct comparison of our results to previous and possibly future study results.”
Self-citationEarly stages of tau pathology and its associations with functional connectivity, atrophy and memory
Berron, D., Vogel, J. W., Insel, P. S., Pereira, J. B., Xie, L., Wisse, L. E. M., Yushkevich, P. A., Palmqvist, S., Mattsson-Carlgren, N., Stomrud, E., et al. (2021) · Brain · doi:10.1093/brain/awab114 · Cited by 240 · cited 1×
“33 The regions included in this staging scheme encompass early medial temporal lobe subregions (defined using automated segmentation of hippocampal subfields on T 1 -weighted images 34 ) as well as later-stage neocortical regions.”
Self-citationStaging β -Amyloid Pathology With Amyloid Positron Emission Tomography
Mattsson, N., Palmqvist, S., Stomrud, E., Vogel, J., & Hansson, O. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.2214 · Cited by 237
Self-citationLeuzy, A., Smith, R., Ossenkoppele, R., Santillo, A., Borroni, E., Klein, G., Ohlsson, T., Jögi, J., Palmqvist, S., Mattsson-Carlgren, N., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.0989 · Cited by 222 · cited 5×
“21,22,26 Each tau-PET SUVR image was rigidly co-reregistered to a high-resolution T 1 - weighted MRI (Siemens3 T MAGNETOM Prisma) scan, performed a maximum of 6 months from the tau-PET scan.”
InfluentialSelf-citationTau-positron emission tomography correlates with neuropathology findings.
Lowe, V. J., Lundt, E. S., Albertson, S. M., Min, H., Fang, P., Przybelski, S. A., Senjem, M. L., Schwarz, C. G., Kantarci, K., Boeve, B., et al. (2020) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.09.079 · Cited by 203
Leuzy, A., Janelidze, S., Mattsson-Carlgren, N., Palmqvist, S., Jacobs, D., Cicognola, C., Stomrud, E., Vanmechelen, E., Dage, J. L., & Hansson, O. (2021) · Neurology · doi:10.1212/wnl.0000000000012727 · Cited by 128
Self-citationPredicting future rates of tau accumulation on PET
Jack, C. R., Wiste, H. J., Weigand, S. D., Therneau, T. M., Lowe, V. J., Knopman, D. S., Botha, H., Graff-Radford, J., Jones, D. T., Ferman, T. J., et al. (2020) · Brain · doi:10.1093/brain/awaa248 · Cited by 117 · cited 1×
“While APOE ɛ 4 carriership has previously been shown to not affect longitudinal tau-PET change, 51 the potential effects of APOE ɛ 4 on cognitive decline 52 warrants further investigation of the associations between APOE genotype and the A+P+T − biomarker profile.”
Correlation of In Vivo [18F]Flortaucipir With Postmortem Alzheimer Disease Tau Pathology
Smith, R., Wibom, M., Pawlik, D., Englund, E., & Hansson, O. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2018.3692 · Cited by 111 · cited 1×
“12,45,46 Indeed, it has been previously reported that CSF p-tau and tau-PET differentially affect atrophy and cognition, 47 with tau-PET being more strongly associated with both atrophy and cognition.”
Self-citationHead-to-head comparison of tau positron emission tomography tracers [18F]flortaucipir and [18F]RO948
Smith, R., Schöll, M., Leuzy, A., Jögi, J., Ohlsson, T., Strandberg, O., & Hansson, O. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04496-0 · Cited by 88
Self-citationTowards clinical application of tau PET tracers for diagnosing dementia due to Alzheimer's disease
Ossenkoppele, R., & Hansson, O. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12356 · Cited by 62
Self-citation
Cited by
Blood biomarkers for Alzheimer’s disease in clinical practice and trials
Hansson, O., Blennow, K., Zetterberg, H., & Dage, J. (2023) · Nature Aging · doi:10.1038/s43587-023-00403-3 · Cited by 522
Self-citationTherriault, J., Vermeiren, M., Servaes, S., Tissot, C., Ashton, N. J., Benedet, A. L., Karikari, T. K., Lantero-Rodriguez, J., Brum, W. S., Lussier, F. Z., et al. (2023) · JAMA Neurology · doi:10.1001/jamaneurol.2022.4485 · Cited by 272
Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads
Salvadó, G., Ossenkoppele, R., Ashton, N. J., Beach, T. G., Serrano, G. E., Reiman, E. M., Zetterberg, H., Mattsson‐Carlgren, N., Janelidze, S., Blennow, K., et al. (2023) · EMBO Molecular Medicine · doi:10.15252/emmm.202217123 · Cited by 205
“This is important when interpreting p-tau measures in the A/T/N (Jack et al , 2016) context, as they may be more related to A (amyloid) than previously thought, as recently suggested (Groot et al , 2022; Moscoso et al , 2022; Therriault et al , 2022).”
MethodSelf-citationBoccalini, C., Ribaldi, F., Hristovska, I., Arnone, A., Peretti, D. E., Mu, L., Scheffler, M., Perani, D., Frisoni, G. B., & Garibotto, V. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13355 · Cited by 82
APOEε4 potentiates amyloid β effects on longitudinal tau pathology
Ferrari-Souza, J. P., Bellaver, B., Ferreira, P. C. L., Benedet, A. L., Povala, G., Lussier, F. Z., Leffa, D. T., Therriault, J., Tissot, C., Soares, C., et al. (2023) · Nature Aging · doi:10.1038/s43587-023-00490-2 · Cited by 43
Metadata
- Authors
- Groot, C., Smith, R., Stomrud, E., Binette, A. P., Leuzy, A., Wuestefeld, A., Wisse, L. E. M., Palmqvist, S., Mattsson-Carlgren, N., Janelidze, S., Strandberg, O., Ossenkoppele, R., & Hansson, O.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2022-09-09
- Volume
- 146
- Issue
- 4
- Pages
- 1580-1591
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W4295227033
- Cited by
- 50
- References
- 35
- FWCI
- 5.96
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.